Patents by Inventor Omid Veiseh

Omid Veiseh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250136910
    Abstract: In some embodiments, devices for use as blood-brain barrier models are disclosed. The devices may include either a hydrogel component that surrounds a channel formed between a first opening and a second opening of the hydrogel component, or a hydrogel component that forms a groove. The devices may further include pericytes disposed in the channel or the groove, and endothelial cells may be disposed in the channel or the groove. The hydrogel component may include astrocytes (e.g., printed into the hydrogel component via projection stereolithography). Also disclosed are various methods of making and using these devices.
    Type: Application
    Filed: October 16, 2024
    Publication date: May 1, 2025
    Applicants: Merck Sharp & Dohme LLC, William Marsh Rice University
    Inventors: Nicole L. Buist, Martha J. Fowler, Yufang He, Anna Kristen Mai, Adam T. Procopio, Madison K. Royse, Omid Veiseh, Jun Xu
  • Publication number: 20250090725
    Abstract: Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.
    Type: Application
    Filed: November 19, 2024
    Publication date: March 20, 2025
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Robert S. Langer, Daniel G. Anderson
  • Patent number: 12186453
    Abstract: Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: January 7, 2025
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Robert S. Langer, Daniel G. Anderson
  • Publication number: 20250000788
    Abstract: Described herein are implantable devices comprising living cells and an extended release formulation of a glucocorticoid.
    Type: Application
    Filed: January 26, 2022
    Publication date: January 2, 2025
    Inventors: Sofia Brites Boss, Christopher P. Hencken, Hozefa Bandukwala, Robert James Miller, Omid Veiseh, Devyn McKinley Smith
  • Publication number: 20240415931
    Abstract: A fundamental barrier to successful device-based therapies is the Inability to deliver a sustained amount of therapeutics that do not have a systemic toxic impact on the subject. Thus, there is a need for identifying new compositions and methods to enhance the delivery, distribution, and/or efficacy of therapeutic agents. The present disclosure relates to implantable constructs (encapsulated cells) designed to deliver antigenic therapeutic reagents, such as IL-2, and optionally one additional therapeutic.
    Type: Application
    Filed: October 19, 2022
    Publication date: December 19, 2024
    Applicant: William Marsh Rice University
    Inventors: Omid VEISEH, Amanda NASH, Samira AGHLARA-FOTOVAT
  • Patent number: 12161760
    Abstract: Described herein are particles comprising a first compartment, a second compartment, and a compound of Formula (I), as well as compositions and methods of making and using the same. The particles may comprise a cell capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: December 10, 2024
    Assignee: SIGILON THERAPEUTICS, INC.
    Inventors: Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Matthias Alexander Oberli, Owen O'Connor, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Paul Kevin Wotton
  • Patent number: 12097307
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: September 24, 2024
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Arturo Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Publication number: 20240301093
    Abstract: Disclosed herein are compounds of the formula: A-L-R1(I), wherein the these variables are defined herein, as well as medical devices comprising said compounds. The present disclosure also provides pharmaceutical compositions comprising the compounds or medical devices disclosed herein. Further, the present disclosure provides methods of treatment using the compounds, medical devices, or pharmaceutical compositions disclosed herein.
    Type: Application
    Filed: June 14, 2022
    Publication date: September 12, 2024
    Applicant: William Marsh Rice University
    Inventors: David ZHANG, Ping SONG, Omid VEISEH, Siavash PARKHIDEH, Sudip MUKHERJEE, Maria Isabel RUOCCO, Boram KIM, Michael David DOERFERT, Yuxuan CHENG
  • Publication number: 20240279187
    Abstract: The present invention provides compounds, e.g., compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are implantable elements (e.g., devices and materials) comprising the same, as well as methods of use thereof, e.g., for treating or preventing a disease, disorder, or condition.
    Type: Application
    Filed: December 5, 2023
    Publication date: August 22, 2024
    Inventors: Omid Veiseh, Richard Heidebrecht, Paul Kevin Wotton, Matthias Alexander Oberli, Robert James Miller
  • Publication number: 20240254507
    Abstract: An engineered cell expressing a therapeutic agent and a reporter agent, the engineered cell comprising a first transgene containing a light sensing DNA sequence encoding a light sensing protein, and a second transgene containing a calcium activated promoter, a therapeutic agent DNA encoding a therapeutic agent, and a reporter agent DNA encoding a reporter agent.
    Type: Application
    Filed: April 21, 2022
    Publication date: August 1, 2024
    Inventors: Omid Veiseh, Jacob Robinson, Jonathan Rivnay, Isaac Hilton, Samantha T. Fleury, Matthew C. Parker, Jacob H. Goell, Jing Li, Kaiyuan Wang
  • Publication number: 20240207508
    Abstract: A bioelectronic implantable device includes engineered cells and an electronically controlled stimulator that regulates a quantity and timing of therapeutic agent produced by the engineered cells.
    Type: Application
    Filed: April 21, 2022
    Publication date: June 27, 2024
    Inventors: Jonathan Rivnay, Omid Veiseh, Jacob Robinson, Samantha T. Fleury, Matthew C. Parker, Fatima T. Alrashdan
  • Publication number: 20240189505
    Abstract: A bioelectronic wearable device includes engineered cells and an electronically controlled stimulator that regulates a quantity and timing of therapeutic agent produced by the engineered cells.
    Type: Application
    Filed: April 21, 2022
    Publication date: June 13, 2024
    Inventors: Jonathan Rivnay, Omid Veiseh, Jacob Robinson
  • Publication number: 20240189458
    Abstract: The present disclosure provides compositions comprising encapsulated engineered bacteria. The bacteria may be engineered to act as sensors of biomarkers, such as inflammation, as well as to produce diagnostic or therapeutic agents.
    Type: Application
    Filed: June 15, 2022
    Publication date: June 13, 2024
    Applicants: William Marsh Rice University, Baylor College of Medicine
    Inventors: Jeffrey TABOR, Omid VEISEH, Robert BRITTON, Moshe BARUCH, Annie GOODWIN, Elena MUSTEATA, Michael DOERFERT, Samira AGHLARA-FOTOVAT, Maxwell HUNT
  • Patent number: 11945786
    Abstract: The present invention provides compounds, e.g., compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are implantable elements (e.g., devices and materials) comprising the same, as well as methods of use thereof, e.g., for treating or preventing a disease, disorder, or condition.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: April 2, 2024
    Assignee: SIGILON THERAPEUTICS, INC.
    Inventors: Omid Veiseh, Richard Heidebrecht, Paul Kevin Wotton, Matthias Alexander Oberli, Robert James Miller
  • Publication number: 20240041755
    Abstract: The present disclosure relates to implantable constructs and related compositions comprising a plurality of cells producing antigens and/or immune effector molecules.
    Type: Application
    Filed: December 17, 2021
    Publication date: February 8, 2024
    Applicant: William Marsh Rice University
    Inventors: Omid VEISEH, Amanda NASH, Boram KIM, Damon BERMAN, Lauren CHENG, David ZHANG
  • Publication number: 20240041939
    Abstract: The present disclosure relates to implantable constructs (encapsulated cells) designed to deliver therapeutic reagents, such as IL-12 and/or IL-12 and methods of using the same to treat conditions, such as cancer.
    Type: Application
    Filed: December 16, 2022
    Publication date: February 8, 2024
    Applicant: William Marsh Rice University
    Inventors: Omid VEISEH, Amanda NASH, Samira AGHLARA-FOTOVAT
  • Publication number: 20230265149
    Abstract: The present disclosure relates to implantable constructs (encapsulated cells) designed to deliver antigenic therapeutic reagents, such as IL-2.
    Type: Application
    Filed: October 19, 2022
    Publication date: August 24, 2023
    Applicant: William Marsh Rice University
    Inventors: Omid VEISEH, David ZHANG, Sudip MUKHERJEE, Maria RUOCCO, Michael DOERFERT, Amanda NASH, Samira AGHLARA-FOTOVAT
  • Publication number: 20230210908
    Abstract: The present disclosure provides expression constructs designed to provide for expression of therapeutic proteins from engineered cells. The engineered cells may be encapsulated into implantable elements that allow for the therapeutic protein to be released into from the capsule while protecting the cell from the immune system of a patient into which the capsule is implanted.
    Type: Application
    Filed: February 11, 2021
    Publication date: July 6, 2023
    Applicant: William Marsh Rice University
    Inventors: Omid VEISEH, Amanda NASH, Bhagyashree Kishor BACHHAV, Carlos Alberto ORIGEL MARMOLEJO, Damon BERMAN, Christian SCHREIB, Laura SEGATORI, Alen TRUBELJA, Oleg A. IGOSHIN, Andrew D. HECHT
  • Publication number: 20230123802
    Abstract: Described herein are RPE cells engineered to secrete a FVII protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating a patient with hemophilia or FVII deficiency.
    Type: Application
    Filed: March 27, 2020
    Publication date: April 20, 2023
    Inventors: Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Owen O'Connor, Matthias Alexander Oberli, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Paul Kevin Wotton, Zoe Yin
  • Publication number: 20230054899
    Abstract: Provided herein are high-throughput methods for genetic barcoding and analysis, e.g., for tagging each biomaterial apsule with a barcode cell. These barcode cells are derived from patient samples, and thus embody natural human genetic variation. Also provided are SNP panels that can be used as genetic barcodes to identify the identity of a cell.
    Type: Application
    Filed: January 14, 2021
    Publication date: February 23, 2023
    Applicant: William Marsh Rice University
    Inventors: David Yu ZHANG, Ping SONG, Omid VEISEH, Siavash PARKHIDEH, Sudip MUKHERJEE, Maria Isabel RUOCCO, Boram KIM, Yuxuan CHENG